Stability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperatures

Therapeutic Drug Monitoring

Volumn 36, Issue 5, 2014, Pages 674-676

  Franceschi, Loretta ^a,b   Cojutti, Piergiorgio ^a,b   Baraldo, Massimo ^a,b   Pea, Federico ^a,b  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

concentrated solutions; continuous infusion; elevated temperature; meropenem; stability

Indexed keywords

MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

AQUEOUS SOLUTION; ARTICLE; CONTINUOUS INFUSION; DRUG DEGRADATION; DRUG STABILITY; ENVIRONMENTAL TEMPERATURE; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PH; PRIORITY JOURNAL; ROOM TEMPERATURE; TEMPERATURE SENSITIVITY; CHEMISTRY; HEAT; INTRAVENOUS DRUG ADMINISTRATION; TIME;

ANTI-BACTERIAL AGENTS; DRUG STABILITY; HOT TEMPERATURE; INJECTIONS, INTRAVENOUS; THIENAMYCINS; TIME FACTORS;

EID: 84930182562     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000054     Document Type: Article

References (11)

1. Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of Beta-lactam antibiotics in severe sepsis: A multicenter double-blind, randomized controlled trial. Clin Infect Dis. 2013;56:236-244.
2. Chytra I, Stepan M, Benes J, et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: A randomized open-label controlled trial. Crit Care. 2012;16:R113.
3. Lorente L, Lorenzo L, Martin MM, et al. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother. 2006;40:219-223.
4. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect. 2011;17:1135-1141.
5. Pea F, Viale P, Cojutti P, et al. Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: A pharmacokinetics/ pharmacodynamics-based approach. Antimicrob Agents Chemother. 2012;56:6343-6348.
6. Berthoin K, Le Duff CS, Marchand-Brynaert J, et al. Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother. 2010;65:1073-1075.
7. Venkatesh M, Bairavi VG, Sasikumar KC. Generic antibiotic industries: challenges and implied strategies with regulatory perspectives. J Pharm Bioallied Sci. 2011;3:101-108.
8. Mendez AS, Steppe M, Schapoval EE. Validation of HPLC and UV spectrophotometric methods for the determination of meropenem in pharmaceutical dosage form. J Pharm Biomed Anal. 2003;33:947-954.
9. Pea F, Cojutti P, Sbrojavacca R, et al. TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient. Ann Pharmacother. 2011;45:e37.
10. Viaene E, Chanteux H, Servais H, et al. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother. 2002;46:2327-2332.
11. Keel RA, Sutherland CA, Crandon JL, et al. Stability of doripenem, imipenem and meropenem at elevated room temperatures. Int J Antimicrob Agents. 2011;37:184-185.